Moreover, more recent studies, such as the Declare TIMI 58 trial, also did not present extractable results of glycemic control in randomized patients (10), and neither did the trials that randomized patients with heart failure to SGLT-2 inhibitors, DAPA-HF, Emperor Reduced and Emperor Preserved Trials (21-23). This evidence concerns the gene SLC5A2 and hydrops fetalis.